Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project, we analyzed a total of 44 drug sensitivity prediction algorithms. The top-performing approaches modeled nonlinear relationships and incorporated biological pathway information. We found that gene expression microarrays consistently provided the best predictive power of the individual profiling data sets; however, performance was increased by including multiple, independent data sets. We discuss the innovations underlying the top-performing methodology, Bayesian multitask MKL, and we provide detailed descriptions of all methods. This study establishes benchmarks for drug sensitivity prediction and identifies approaches that can be leveraged for the development of new methods.
A n A ly s i s
Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project, we analyzed a total of 44 drug sensitivity prediction algorithms. The top-performing approaches modeled nonlinear relationships and incorporated biological pathway information. We found that gene expression microarrays consistently provided the best predictive power of the individual profiling data sets; however, performance was increased by including multiple, independent data sets. We discuss the innovations underlying the top-performing methodology, Bayesian multitask MKL, and we provide detailed descriptions of all methods. This study establishes benchmarks for drug sensitivity prediction and identifies approaches that can be leveraged for the development of new methods.
The success of precision medicine hinges on our ability to effectively translate genomic data into actionable, customized prognosis and treatment regimens for individual patients. This requires identifying a genomic disease signature from a patient, then matching it with the most effective therapeutic intervention. As a scientific community, we are moving toward this goal, but many questions still remain, including, what data are needed to develop these genomic signatures and what methods are needed to extract the appropriate information from high-dimensional genomic data sets? The first step in addressing these challenges is to generate comprehensive drug sensitivity profiling measurements across many drugs, many disease (sub)types, and many genomic profiling technologies. Several of these data sets have been generated with a focus on cancer biology [1] [2] [3] [4] [5] [6] [7] [8] [9] , and in particular breast cancer 4, 5, [10] [11] [12] [13] [14] . From these data, the bottleneck then becomes identifying robust computational approaches that connect genomic profiles to drug and disease response.
In the past 20 years, there has been measurable improvement in breast cancer outcomes with a steady decrease in mortality 15 . The identification of HER2 amplification and subsequent discovery of HER2-targeted therapies (e.g., trastuzumab (Herceptin), lapatinib (Tykerb)) demonstrates that the identification of genomic biomarkers can be used to effectively guide treatment decisions and improve outcomes. However, identification of such biomarkers is complicated by substantial genomic and epigenomic heterogeneity in breast cancer 2, 10, 16, 17 , indicating that multiple 'drivers' may serve as targets for breast cancer treatment. Effective personalized treatments will require matching therapeutic interventions to the complex genomic context of each patient.
The ideal data set(s) to build predictive models linking genomic context to treatment would be systematically characterized drug sensitivities across a large cohort of patients, but these data are time-intensive to generate, prohibitively expensive, and limited in the scope of drugs that can be tested. Performing such assays in cell culture and focusing on breast cancer affords the opportunity to learn the factors that contribute to building effective predictive models in a tractable biological system; these factors can then be used for the design of marker-based clinical trials. Comparisons have shown that cell lines mirror many aspects of the 'omic' diversity found in primary tumors 4, 18, 19 , suggesting that they can be used as a proxy for characterizing the response to therapeutic interventions. Previous work has characterized relationships between genomic profiles and drug response 1, 3, 6, 7, 20 and several drug sensitivity prediction algorithms have been proposed 1, 3, [20] [21] [22] [23] ; however, a thorough and unbiased comparison of such methods has not been reported.
The Dialogue for Reverse Engineering Assessment and Methods (DREAM) project (http://www.the-dream-project.org/) is the ideal framework to assess predictive models from researchers across the world. The DREAM project is organized around a community of data scientists, where high-impact data along with challenges are presented annually, participants submit their best models, and unbiased assessment is performed using standardized metrics and blinded gold standards. This effort results in a rigorous assessment and performance ranking of methods, and cultivates a community of scientists interested in biomedical research problems.
In collaboration with the NCI, we developed the NCI-DREAM drug sensitivity prediction challenge with the goal of identifying and benchmarking top-performing methods for predicting therapeutic response from genomic, proteomic, and epigenomic profiling data (hereafter referred to as profiling data sets) in breast cancer cell lines. The scientific community submitted 44 sets of predictions, providing a rich sampling of state-of-the-art algorithms. The submissions were rigorously scored against an unpublished and hidden gold-standard data set. We identify the top-performing methods and discuss the details of the top two performers. We relate trends in methodologies to overall performance, in particular, modeling nonlinearities in the data and the benefit of using prior knowledge, often in the form of biological pathways. Finally, we provide an analysis of the tested therapeutic compounds and cell line profiling data sets.
RESULTS

Summary of data sets and challenge
We assembled a panel of 53 breast cancer cell lines, which have been previously profiled for DNA copy-number variation, transcript expression, mutations, DNA methylation and protein abundance 20 . In addition, dose-response values of growth inhibition were compiled for each cell line exposed to 28 therapeutic compounds (Fig. 1) . (See Online Methods for a detailed description of the profiling data sets.)
Outlined in Figure 1 , participants were supplied with the full set of profiling data for all 53 cell lines, and drug response data for 35 cell lines for the 28 compounds. The gold-standard evaluation data set, which was hidden from the participants, consisted of drug-response data for the remaining 18 cell lines. Cell lines were assigned to the training and test data sets to ensure a balance of breast cancer subtypes.
Participants were challenged to predict a ranked list of the most sensitive (to be ranked first) to most resistant (to be ranked last) cell lines for each individual drug across all the 18 test cell lines. Assessment of predictions was based on participant's ranking of all 28 therapeutic compounds across all 18 test cell lines.
Characterizing methods to predict drug sensitivity Participants submitted 44 sets of predictions that cover a range of methodologies. We assigned submissions to one of six categories: (i) kernel methods, (ii) nonlinear regression (regression trees), (iii) sparse linear regression, (iv) PLS (partial least-squares) or PC (principal component) regression, (v) ensemble/model selection and (vi) other (those methods not falling cleanly into the previous five categories). All methods are listed in Table 1 with a short description that covers pre-and postprocessing, along with the underlying methodology (expanded team summarizations can be found in Supplementary Table 1) .
Preprocessing and feature selection are core components of building a predictor. In this challenge, features in the profiling data sets (P) far outnumber the total samples (N), increasing the risk of overfitting. To address this, teams often reduced the number of features modeled by correlating the features in the profiling data set to the doseresponse data. Other preprocessing steps included principal component analysis, regularized regression (e.g., lasso, ridge or elastic nets) and mapping gene-level measurements to biological pathways.
Postprocessing includes summarizing or integrating predictions from individual algorithms or data sets into a final set of predictions. For instance, many participants built models for each of the six profiling data sets individually, and then integrated these models to derive the final cell line response predictions for submission. Most frequently, teams computed a weighted average across individual profiling data set predictions. Detailed descriptions of team methods can be found in Supplementary Note 1.
Evaluating drug sensitivity predictions Team predictions were scored using a modified version of the concordance index (c-index) 24 , the probabilistic c-index (pc-index), where variation in the experimentally determined dose-response measurements was directly incorporated into the calculation. We present all dose-response values as −log 10 (GI 50 ), where GI 50 is the concentration that inhibited cell growth by 50% after 72 hours of treatment. Raw dose-response measurements can be found in Supplementary  Table 2 . A team's final score was calculated as the weighted average of the pc-index for all 28 tested compounds, which we termed the weighted, probabilistic c-index (wpc-index, see Online Methods and Supplementary Note 3). Drug weights reflect the statistical significance of the gold-standard cell-line ranking compared to a distribution of randomly generated predictions. We note that the range of the wpc-index will change according to experimental variation in the dose-response measurements, thus we also report a scaled version of the wpc-index to map the values to the range [0,1]. To verify scoring consistency, we also evaluated teams using a resampled Spearman correlation approach (Online Methods). Results from both scoring methods were consistent (ρ = 0.89; Supplementary Fig. 1) ; we present the wpc-index results in Table 1 Table 4 and Supplementary  Fig. 2 ) and found a tight relationship between this measure of accuracy and the wpc-index (ρ = 0.78; Supplementary Fig. 3 ). For the top-performing method, wpc-index = 0.583, which corresponds to a balanced accuracy = 0.78. Details of this analysis can be found in Supplementary Note 2 with a mapping of the wpc-index to the sensitive and resistant balanced accuracy in Supplementary Table 5 .
To evaluate the significance of an individual team score, we compared the wpc-index to a null model of randomly predicted dose-response values. For 34 of the 44 teams, the null model of randomly generated predictions could be rejected (two-sided, t-test, false-discovery rate (FDR) < 0.05) (Fig. 2a) . These results indicate that many diverse methods can be implemented to make drug sensitivity predictions from pretreatment profiling data sets. Consistent with previous DREAM challenge results 25 , we observed that no single method category consistently outperformed the others (Fig. 2a and Table 1 ). This suggests that the separation in performance is heavily based on factors such as feature selection and method-specific implementations. Examples of innovative approaches from the two top-performing teams are presented in the following section.
All submissions were subjected to a robustness (resampling) analysis by randomly masking 10% of the gold-standard data set, then recalculating team scores (Fig. 2b,c) . From this analysis, the top two teams were reliably ranked the best and second best, both when comparing team scores (one-sided, Wilcoxon signed-rank test, FDR < 10 −10 ; Fig. 2b ) and team ranks (one-sided, Wilcoxon A n A ly s i s npg A n A ly s i s signed-rank test, FDR < 10 −10 ; Fig. 2c ). When directly compared, the top-ranked team outperformed the second-best team for 91%, and the remaining teams, for over 99% of the resampled iterations. The second-best team outperformed the remaining teams for over 95% of the resampled iterations ( Supplementary Fig. 4 and Supplementary Table 6); however, the third through fourteenth ranked teams were not statistically different (Supplementary Tables 6 and 7) .
Of the 44 submissions, 23 used all six profiling data sets to make their predictions, 8 used five data sets, 4 used three data sets, 5 used two data sets and 4 used one data set. We compared the average rank performance of teams that used all six profiling data sets to teams using five or fewer data sets, but did not find a significant difference in their performance (average rank 22.7 versus 22.3). We explored several additional variables (missing values being imputed, outside information being used, method category) and found that only the inclusion of outside information in the form of annotated biological pathways 26, 27 or published drug response data sets 1, 3, 4 improved the average team rank (17.4 versus 24.9; one-sided, Wilcoxon rank-sum test, p = 0.03).
The observation that integrating predictions across multiple, independent teams produces the most robust score has been previously made 25 HCC202  HCC1954  HCC1806  HCC1428  HCC1395  HCC1569  HCC1143  HCC1187  HCC38  SUM52PE  MCF10A  SUM225CWN  LY2  HCC2185  HCC3153  ZR75B  SKBR3  600MPE  SUM149PT  SUM159PT  SUM1315MO2  SUM185PE  184A1  184B5  21MT1  MX1  21NT  HCC1937  HS578T  ZR7530  MCF12A  T47DKBLUC  MCF10F  MDAMB453  MDAMB361  MDAMB134VI  MDAMB231  MDAMB157  MDAMB175VII  CAMA1  AU565  T47D  BT20  UACC812  BT549  SUM229PE  BT483  MCF7  HCC1419  BT474  MDAMB415 TCS PIM-11 (PIM1) Chloroquine Figure 1 The NCI-DREAM drug sensitivity challenge. (a) Six genomic, epigenomic, and proteomic profiling data sets were generated for 53 breast cancer cell lines, which were previously described 23 . Drug responses as measured by growth inhibition were assessed after treating the 53 cell lines with 28 drugs. Participants were supplied with all six profiling data sets and dose-response data for 35 cell lines and all 28 compounds (training set). Cell line names were released, but drug names were anonymized. The challenge was to predict the response (ranking from most sensitive to most resistant) for the 18 held-out cell lines (test set). The training and test cell lines were balanced for cancer subtype, dynamic range and missing values ( Supplementary Fig. 11 ). Submissions were scored on their weighted average performance on ranking the 18 cell lines for 28 compounds. Nonlinear regression (regression trees) 1 Features were randomly selected to built an ensemble of unpruned regression trees for each dataset, missing values were imputed, weights for the models were calculated, final predictions were made using a weighted sum of the individual models. Gene features were selected using linear regression and maximal information coefficient, pathway information was also used to derive features, training and prediction was done using a random forest model.
Random forests were constructed in a stacked approach, an ensemble of regression trees was constructed for all drug/dataset pairs, missing values were imputed, predictions were made for individual models and another random forest was used to combine the different predictions for the drugs to a final prediction. Features were removed with low dynamic range, missing feature values were imputed, training and predictions were made using lasso regression on individual datasets, final predictions were made using the weighted sum of regression models.
0.539(0.560) 1.9 × 10 −2 exnmrc 7 Statistically significant features were selected using Spearman correlation, training and prediction were done using an elastic net.
0.532(0.549) 4.7 × 10 −2 e 8 Features were constructed by grouping genes according to GO terms, training and prediction were done using relaxed lasso regression.
0.531(0.548) 4.7 × 10 −2 en OI 9 Gene and pathway features were determined using a one-dimension factor analysis, training and predictions were made with spike and slab multitask regression, GI 50 values were used.
0.531(0.547) 4.9 × 10 −2 exnmrc OI 10 Features were selected using a regression with log penalty, which bridges the L0 and L1 penalty, missing values were imputed, penalized regression models were trained on individual datasets, final predictions were made using a weighted average. Statistically significant features were selected using correlation, models were fit using principal component regression, final predictions were made using a weighted average of models.
0.524(0.538) 9.2 × 10 −2 en
Ensemble/model selection 1 Features were selected using correlation, dimensionality reduced using principal component analysis, lasso and ridge method, several regression models were trained for individual drugs and the top cross-validated model was selected to make final predictions for each drug. The use of outside information, often in the form of biological pathway annotation, was found to be a factor that improved average team rank and is noted in the Data column as 'OI'. Additional method characterizations can be found in Supplemental Table 1 .
and found that the wisdom of crowds resulted in better performance (Supplementary Fig. 5a ), along with increasingly robust predictions (i.e., greater mean, lower variance), by integrating greater numbers of teams (Supplementary Fig. 5b) . Furthermore, predictions from the aggregation of a random subset of methods were very often better than the best of the individual methods in that subset ( Supplementary  Fig. 5c ). These results indicate that individual team methods do provide complementary sets of predictions.
Top-performing methods exploit nonlinear modeling
The top-performing team from Aalto University and the University of Helsinki (co-authors on this manuscript) developed a machinelearning method that integrates multiple profiling data sets and knowledge-enhanced data representations into a nonlinear, probabilistic regression model to learn and predict drug sensitivities for all drugs simultaneously ( Fig. 3 and Supplementary Note 1; source code provided as Supplementary Software). Their Bayesian multitask multiple kernel learning (MKL) method leveraged four machinelearning principles: kernelized regression, multiview learning, multitask learning, and Bayesian inference. The underlying model was kernelized regression, a regression approach that computes outputs from similarities between cell lines, which is analogous to the usage of kernel methods in classification tasks (e.g., support vector machines). In contrast, other regression approaches compute outputs directly from the input features. The kernel formulation 28, 29 has two advantages. First, it reduces the number of model parameters to match the number of samples (training cell lines) and not the number of features. Second, it captures nonlinear relationships between genomic and epigenomic features, and cell-line drug sensitivities.
In multiview learning, heterogeneous input data (views) are integrated into a single model. This makes it possible to include not only different profiling data sets but also various representations of the same data set. For example, gene expression values can be summarized at the pathway level. We use the term 'view' to describe these representations (analogous to views in a database). Besides the original profiling data sets, three types of computed data views were considered, including gene set summaries, data combinations, and data discretization (Fig. 3a) . Sets of related genes, defined in the MSigDB 27,30 collections C2 (curated gene sets) and CP (canonical pathways), were used to calculate aggregated gene set views (average value for expression data, otherwise maximum). Data combination views were calculated as the product of individual data sets or according to the PARADIGM algorithm 31 . Finally, discretized views were A n A ly s i s compiled by binarizing continuous measures. A total of 22 views were generated. For the kernelized regression, each of the views was converted into a kernel matrix containing pair-wise similarities between all cell lines. Gaussian kernels were used for real-valued views and Jaccard similarity coefficients for binary-valued views. To integrate the views, the team modeled a global similarity matrix as a weighted sum of the view-specific kernel matrices. This approach is known as multiple kernel learning or MKL 32 (Fig. 3b, left) . The kernel weights reflect the relevance of each view for predicting drug sensitivities; the corresponding model parameters are shared across drugs.
The sharing of information between drugs, implying simultaneous modeling of drug sensitivities across all the drugs, is called multitask learning 33 (Fig. 3b, right) . Here, the kernel weight parameters were shared, providing robustness to the overall model. The second set 
where N is the number of training cell lines. Specifically, the Gaussian kernel was used for real-valued data, and the Jaccard similarity coefficient for binary-valued data. Multiview learning: a combined kernel matrix K * was constructed as a weighted sum of the view-specific kernel matrices K k , k = 1,…,K. The kernel weights were obtained by multiple kernel learning. Multitask learning: training was performed for all drugs simultaneously, sharing the kernel weights across drugs but allowing for drug-specific regression parameters, which for each drug consisted of a weight vector for the training cell lines and an intercept term. Bayesian inference: the model parameters were assumed to be random variables that follow specific probability distributions. Instead of learning point estimates for model parameters, the parameters of these distributions were learned using a variational approximation scheme. A n A ly s i s of model parameters comprises the core parameters of kernelized regression, which were drug-specific: for each drug, there was a vector of weights for the training cell lines and an individual intercept term. To handle the uncertainty resulting from the small sample size, all model parameters were learned by Bayesian inference, assuming for each model parameter a specific probability distribution, where parameters were learned using a computationally efficient variational approximation scheme (Supplementary Note 1) . After being benchmarked against the Genomics of Drug Sensitivity in Cancer (GDSC) data set 3 , the Bayesian multitask MKL method was applied to the NCI-DREAM test cell lines. By training the model with all 22 views, predictive performance was improved by 9% over using only the six profiling data sets, yielding a final wpc-index = 0.583 (one-sided, t-test from random predictions, FDR = 2.5 × 10 −5 ; scaled wpc-index = 0.629).
The second-best performing team of Qian Wan and Ranadip Pal from Texas Tech University leveraged the strengths of random forest regression 34 to account for nonlinearities in the NCI-DREAM data (Supplementary Note 1) . First, an ensemble of unpruned regression trees with random feature selection was compiled based on a bootstrapped sampling of a given profiling data set. For each profiling data set, a final model based on averaging of predictions over the collection of trees was generated. Each model was then weighted according to its least-squares fit to the training drug sensitivity data. The final predictions were calculated as the weighted sum of all six profiling data set models, yielding a final wpc-index = 0.577 (one-sided, t-test, FDR = 7.2 × 10 −5 ; scaled wpc-index = 0.620). For this approach, the most informative profiling data sets were gene expression followed by methylation.
Profiling data sets provide nonredundant predictive signals
We used the insights provided by participating teams in a postchallenge comparative analysis between the Bayesian multitask MKL method (kernel 1) and an elastic net to characterize the predictive power of the original six profiling data sets. Teams most often reported that gene expression microarrays carried the greatest weight in their models (Supplementary Note 1) . We tested this observation by performing 50 independent simulations of the NCI-DREAM challenge, randomly splitting all data sets into 35 training and 18 test cell lines, balanced for breast cancer subtype. To establish a baseline performance, we chose an elastic net model because it had been used previously 1 , was widely used by teams (Supplementary Note 1) , and could be easily applied off-the-shelf (glmnet R package 35 ). Averaged across all tested drugs, we found that the RPPA data showed the highest performance for the elastic net, followed closely by gene expression data (Fig. 4a) . The Bayesian multitask MKL performed better than the elastic net using the RPPA data (one-sided, Wilcoxon signed-rank test, FDR = 1.3 × 10 −6 ), and Bayesian multitask MKL using gene expression data significantly outperformed the use of RPPA data (two-sided, Wilcoxon signed-rank test, FDR = 1.3 × 10 −6 ). For both methods, the performance varied across individual drugs (Supplementary Fig. 6 ). We also examined the effect of profiling data sets on drug classes (as defined in Supplementary Table 8 ) and found that for Bayesian multitask MKL, the 'Signaling growth' drugs had higher predictive scores in general, with gene expression and RPPA data being the data sets with the most predictive power (Supplementary Fig. 6 ).
Between the six profiling data sets, we explored the issue of data complementarity and redundancy, specifically, which data set combinations provide performance gains over single data sets. 
A n A ly s i s
Bayesian multitask MKL method, we found that exome sequencing data best complemented gene expression data, whereas for the elastic net, methylation data best complemented gene expression data. For both methods, all other data sets were best complemented by gene expression, to varying degrees (Supplementary Fig. 7) . Additionally, by evaluating methods trained with five instead of the full six profiling data sets, we identified methylation as the most independent, nonredundant profiling data set because removing methylation showed the largest average drop in performance (Supplementary Figs. 7 and 8) .
In addition to the original data sets, we explored the performance of computed data views, as defined in the previous section. For both methods, gene set views (CP and C2) showed improved performance for copy number variation (CNV) data compared to the original data. In contrast, discretization of RNA-seq data improved the performance only with Bayesian multitask MKL and not with the elastic net. Comparing all computed views, the gene set view (CP) of gene expression data achieved the best performance for both methods (Fig. 4b) . Finally, we tested whether all views for a single profiling data set (original data set plus computed views) could be integrated to improve performance. For the elastic net, we only found a slight gain in performance for the RNA-seq and CNV groups, whereas the Bayesian multitask MKL method showed performance gains npg A n A ly s i s for all groups except for exome sequencing (Fig. 4c) , with the topperforming group coming from gene expression data. Notably, the fully integrated model of all 22 data views improved performance against the gene expression group (one-sided, Wilcoxon signed-rank test, FDR = 7.3 × 10 −7 ; Fig. 4d ). Taken together, these results suggest that gene expression data provides the most predictive power for any individual profiling data set. Also, predictive power can be gained within a data set by generating new computational views that integrate across profiling data sets and incorporate prior knowledge. Notably, this improvement comes with no additional experimental cost (Supplementary Figs. 9 and 10) .
A predictive signal can be identified for most drugs Teams were scored according to their ability to rank cell lines across all 28 tested therapeutic compounds. Here, we explored teams' abilities to predict individual drug response. Inhibition of cell growth was predicted well for some compounds (e.g., bromopyruvate (glycolysis), PD184352 (MEK)), whereas for other compounds, teams generally performed poorly (e.g., chloroquinine (autophagy), FR180304 (ERK)) (Fig. 5a ). To characterize factors that influence compound predictability, we measured the Pearson correlation between the pc-index and a compound's dynamic range (minimum to maximum −log 10 (GI 50 ) values). A mild positive trend exists (ρ = 0.14), though it is not statistically significant (p = 0.49) (Fig. 5b) . We found that proteasome inhibitors tend to be predicted more accurately than other drug classes (as defined in Supplementary Table 8) , though with a relatively small number of compounds in each class, this analysis is not well-powered. One factor that did confound our assessment of individual drug performance was the number of −log 10 (GI 50 ) values measured for a drug (Fig. 5b) . That is, missing values and multiple cell lines with the same measured response resulted in underpowered, drug-specific statistics. This observation is the basis for weighting drugs to calculate the wpc-index score. We further assessed the predictability of individual drugs by comparing the distribution of team predictions to a random model and found that 21/28 drugs performed better than the average null model, and 16/28 drugs were significantly better (Kolmogorov-Smirnov test, FDR < 0.05; Fig. 5c ). This strongly indicates that a predictive signal is being identified by a majority of teams for more than half of the tested compounds. Further, these observations demonstrate that it is possible to identify predictive features for compounds representing diverse modes of action. We also quantified the gap in performance between team predictions and the best possible ranking (as defined by the rank order of the test cell lines). Across 28 compounds, the Bayesian multitask MKL method accounted for 73% of the maximum possible score, with the second-best performing team accounting for 71% of the maximum possible signal. Although promising, this indicates that these drug sensitivity predictions could benefit from further refinement.
DISCUSSION
Over a period of 5 months, 127 researchers focused their time and efforts on addressing the challenge of drug sensitivity prediction. To our knowledge, no previous studies have assessed a comprehensive benchmarked set of algorithms for predicting therapeutic response based on genomic, epigenomic, and proteomic profiles of untreated cells. The Bayesian multitask MKL method provides an excellent example of how the NCI-DREAM challenge drove innovation in algorithm development. Considering all 44 submitted methods, the insights gained provide a valuable resource for future algorithm development (Supplementary Note 1) .
In particular, our analysis of this collection of algorithms revealed several insights about predicting drug sensitivity. First, we found that modeling nonlinearities in the data was a common component of topperforming methods. Second, the Bayesian multitask MKL method showed improved performance by learning weights for the input data sets. Sharing the weights across drugs provided greater robustness of the prediction model and resulted in an increased overall performance, particularly for the drugs with many missing values. Finally, the application of prior knowledge, particularly in the form of biological pathways, improved drug sensitivity predictions. This was demonstrated in the Bayesian multitask MKL method through data views, though many top-performing teams implemented similar approaches to leverage pathway information.
We observed that gene expression was the most informative data set in many approaches, which may partly reflect the fact that analysis tools for this data type are more abundant and advanced. That is, we do not yet know the best approaches to extract predictive information from the other large profiling data sets; in particular the sparsity of exome sequencing data requires novel analysis methods 36 . However, when combined with expression data, these other data sets can enhance prediction performance.
The analysis of individual compounds showed that predictors of response could be robustly identified for the majority of compounds tested. This suggests a prioritization scheme for identifying compounds and their associated signatures with the most promise for validation in patient populations. Both targeted and nontargeted compounds, as well as those with both high and low dynamic ranges of response could be predicted, indicating that predictive features are present in the profiling data sets for a diverse array of drug mechanisms.
The −log 10 (GI 50 ) drug response measurement used in this study represents one available metric to quantify drug response. Recent studies have demonstrated that dose-response curves can be parameterized in many meaningful ways 1, 37 . It is possible that applying the algorithms assessed here to other parameters of the curves would yield more robust predictions for some of the compounds for which predictions were poor. In addition, the −log 10 (GI 50 ) reflects the combined effect of growth inhibition and apoptosis, two related but distinct processes that can be modeled separately, and even targeted separately as a cancer treatment strategy 38 . Expanding the measurements to include endpoints that mediate oncogenic behavior of cells 39 would allow for improved model construction and has recently been shown to be experimentally and technologically feasible 40 .
A limitation of this work is the small number of cell lines and compounds tested. The efforts by NCI-DREAM participants have laid the groundwork for the development of improved drug sensitivity models that can be applied to newly generated data sets 1, 3 . Another consideration is that preclinical work is only a very early step in the translation to clinical samples. Now that genomic, epigenomic and/or proteomic profiles are frequently a component of clinical trials (e.g., I-SPY 2 Trial: http://www.ispy2.org/), these data will be available to test and refine models developed from this challenge in human trials. Moreover, participants were not given any information about the mode of action, target or chemical structure of the compounds, which could be included as additional features for the models 23 .
The success of precision medicine will depend on our ability to translate large compendia of genomic, epigenomic, and proteomic data into clinically actionable predictions. Examples such as the recent Sage Bionetworks-DREAM breast cancer prognosis challenge 41 and this NCI-DREAM drug sensitivity challenge demonstrate the evolution of challenge-based competitions, resulting in rapid advancement of robust algorithms and establishment of benchmarked A n A ly s i s models. Equally important, challenge-based competitions build the critical mass of collaborative scientists necessary to address fundamental biomedical questions 42 . The evolution of the DREAM project will continue as the challenges in biomedical research expand to the genome scale.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Challenge data and gold standard. The NCI-DREAM drug sensitivity prediction challenge is outlined in Figure 1 . A total of seven data sets were provided for 53 breast cancer cell lines, as discussed in detail in two recent publications: Heiser et al. 4 and Daemen et al. 23 . The cell lines were selected to represent the major, clinically relevant subtypes of breast cancer, including luminal, basal, claudin-low, ERBB2-amplified, and nonmalignant. The drugs were selected based on data availability (on average, drugs were tested on 80% of the 53 cell lines) and novelty (drug response data were unpublished, not distributed throughout the community of participants, and not available from other sources (Supplementary Note 4) ). Most of the included drugs have not been tested clinically in breast cancer, and therefore have the potential to serve as novel therapeutics.
A total of six genomic, epigenomic and proteomic profiling data sets were collected from untreated cells in growth conditions. Descriptions of each profiling data set can be found in the annotation files associated with each data set supplied through the DREAM website (http://www.the-dream-project.org/). Not all profiling data were collected for every cell line, and drugs were not equally sampled across all of the cell lines.
(1) DNA copy-number variation (CNV). Affymetrix Genome-Wide Human SNP6.0 Array. Copy number ratios were estimated relative to a set of 20 normal samples, and data were segmented using circular binary segmentation (CBS) 43 ;
(2) Transcript expression values. Affymetrix GeneChip Human Gene 1.0 ST microarrays were processed using the R package aroma.affymetrix 44 (over 18,000 expression values); (3) Whole exome sequencing (exome seq). Mutation status was obtained from exome-capture sequencing (Agilent Sure Select system). Mutations across all cell lines were filtered as follows: (i) average sum of the base quality scores of all mismatches in the reads containing the mutant allele ≤ 20; (ii) average number of other mismatches in the reads ≤ 1.5; (iii) average distance of the mutant alleles to the 3′ end of their respective reads between 0.2 and 0.8; (iv) mutant allele read support ≥ 4; (v) number of reads per variant supporting either the reference or mutant allele < 400 (over 33,000 reported mutations); (4) RNA sequencing data (RNA-seq). RNA-seq libraries were prepared using the TruSeq RNA Sample Preparation Kit (Illumina) and Agilent Automation NGS system per manufacturers' instructions. Expression analysis was performed with the ALEXA-seq software package 45 (just under 37,000 RNAs); (5) DNA methylation data. The Illumina Infinium Human Methylation27 BeadChip Kit was used for the genome-wide detection of 27,578 CpG loci, spanning 14,495 genes 46 . GenomeStudio Methylation Module v1.0 was used to express the methylation for each CpG locus as a value between 0 (completely unmethylated) and to 1 (completely methylated) (over 27,000 CpGs); (6) RPPA. An antibody-based method to quantitatively measure protein abundance. RPPA data were generated and preprocessed as previously described 47 (131 proteins assayed).
In addition to the profiling data, drug response for each of the 53 cell lines to 28 drugs was tested. Dose-response curves were generated and the GI 50 [M] was calculated. To estimate the GI 50, a series of assays were done, as previously described 48 . Briefly, cells were treated for 72 h with a set of nine doses of each compound in 1:5 serial dilution. Cell viability was determined using the Cell Titer Glo assay. We used nonlinear least-squares to fit the data with a Gompertz curve. The fitted curve was transformed into a GI curve using the method (http://dtp.nci.nih.gov/branches/btb/ivclsp.html) described in Monks, et al. 49 . In cases where the underlying growth data were of high quality, but the GI 50 was not reached, the values were set to the highest concentration tested. The drug response data were filtered according to previously described criteria 4 . All reported drug response values and calculations for scoring were done using −log 10 (GI 50 ). The complete set of unfiltered raw drug response data is in Supplementary Table 2 .
Participants were supplied with the full set of profiling data for all of the cell lines and drug response data for 35 (of the 53) cell lines for all 28 drugs. The gold-standard evaluation data set consisted of drug response data for the remaining 18 cell lines, which were hidden from the participants. Cell lines were assigned to the training and test data sets to ensure a balanced set of breast cancer subtypes.
Participants were challenged to predict a ranked list of the most sensitive (to be ranked first) to most resistant (to be ranked last) cell lines for each individual drug across all the 18 test cell lines. We note that the drug response values, −log 10 (GI 50 ), ranked from highest to lowest values, correspond to a ranking of the most-sensitive to the most-resistant cell lines. Assessment of predictions was based on participant's ranking of the 18 test cell lines. Participants supplied their final submission as a comma-separated text file with the drugs listed as columns and cell lines listed as rows. The cells in the matrix represent ranks of each cell line for a given drug.
Team scoring. Drug response measurements, −log 10 (GI 50 ), are subject to noise. To account for these uncertainties, a pooled variance, 
